Coming May 2025
Get Early Access
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
195 employees
Mammoth Biosciences: An American biotech firm innovating CRISPR products to improve lives.
HQ
Founded
2017
Mammoth Biosciences is an American biotechnology company focused on harnessing the diversity of nature to develop next-generation CRISPR products. By discovering and developing novel CRISPR systems, the company aims to unlock the full potential of its platform to read and write the code of life, thereby improving human health and well-being.
Mammoth Biosciences has achieved significant milestones in the biotech industry, including pioneering advancements in CRISPR technology. The company is backed by notable investors and has garnered attention for its innovative approach to genetic engineering.
Operating Status
Active
Ownership Type(s)
Venture Capital
Main Product(s)
Crispr Products
Technology
Biotech, GenAI
Model Types
Recurring
Revenue Type(s)
Enterprise, Government
Geographic Exposure
Global
When was Mammoth Biosciences founded?
Mammoth Biosciences was founded in 2017.
Where is Mammoth Biosciences's headquarters located?
Mammoth Biosciences's headquarters is located in South San Francisco, CA, US.
When was Mammoth Biosciences's last funding round?
Mammoth Biosciences's most recent funding round was for $150M (USD) in September 2021.
How many employees does Mammoth Biosciences have?
Mammoth Biosciences has 195 employees as of Feb 5, 2024.
How much has Mammoth Biosciences raised to-date?
As of July 05, 2023, Mammoth Biosciences has raised a total of $264.5M (USD) since Sep 9, 2021.
Add Comparison
Total Raised to Date
$264.5M
USD
Last Update Sep 9, 2021
Last Deal Details
$150M
USD
Sep 9, 2021
Series D
Current Employees
195
Last updated: Feb 5, 2024
No location information available for this company.
Locations
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts